Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Southmark Syndications Group

Latest From Boehringer Ingelheim GMBH

Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot

The latest drug development news and highlights from our FDA Performance Tracker.

Performance Tracker Approvals

Pipeline Watch: Phase III Starts For Itacitinib And AXS-05

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Merck's Lantus Copy Lusduna Poised For US Market Pending Litigation

The Merck and Samsung Bioepis formulation of Sanofi's insulin glargine was tentatively approved by FDA, a designation that permits the drug to enter the market pending the resolution of ongoing patent litigation.

Biosimilars Approvals

Ablynx Adds Sanofi To Its List Of Big Pharma Partners

Sanofi is the latest big pharma, following on from Merck & Co., AbbVie and others, to team up with Belgian Nanobody drug developer Ablynx.

Deals Immune Disorders
See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Southmark Syndications Group
  • Senior Management
  • Arthur Weiss, Pres. & CEO
    Donald Hairb, CFO
  • Contact Info
  • Southmark Syndications Group
    Phone: (214) 241-8787
    2711 LBJ Freeway
    Suite 900
    Dallas, TX 75234-
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register